480 results on '"Chong, Elise A."'
Search Results
52. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
53. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
54. Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer
55. Clinical laboratory mutation analysis performed on aggressive B cell non-Hodgkin lymphoma patient biopsies.
56. No CNS sanctuary for lymphoma from CAR T
57. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
58. The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies
59. Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas
60. Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors
61. Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects
62. A Multi-Institutional Retrospective Analysis of T-Cell Lymphomas with Central Nervous System Relapse
63. Palliative Radiotherapy for Diffuse Large B-cell Lymphoma
64. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis
65. Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy
66. Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas
67. CAR-T for large B-cell lymphomas: the clock is ticking
68. Impact of Genetic Mutations on Survival Following Receipt of Commercial CART19 for Patients Diagnosed with Aggressive B Cell Lymphoma
69. Access and Outcomes of Minority Health Populations Receiving Commercial Anti-CD19 CART Therapy for Non-Hodgkin Lymphoma
70. CD5 Expression in Mature T Cell Lymphoma
71. Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts
72. Safety of CAR-T Cell Therapy in Asymptomatic Patients with Positive Respiratory Viral Testing Prior to CAR-T Infusions
73. TP53 Mutations Detected By Clinical Laboratory Mutation Analysis Predict for Inferior Clinical Outcomes in Patients with Newly-Diagnosed Aggressive B Cell Lymphomas, Including Those with High-Risk Features
74. Worldwide Examination of Patients with CLL Hospitalized for COVID-19
75. Combined Lenalidomide, Low-Dose Dexamethasone, and Rituximab Achieves Durable Responses in Rituximab-Resistant Indolent and Mantle Cell Lymphomas
76. Lenalidomide plus rituximab in patients with rituximab-resistant indolent B-cell and mantle cell lymphomas: 10-year follow-up.
77. Association of PET/CT response assessment prior to CAR T-cell infusion with outcomes after CAR T-cell therapy in aggressive B-cell lymphomas.
78. Post-transplant lymphoproliferative disorder in kidney transplant patients: A multicenter report.
79. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
80. Immunotherapy with cells (article not eligible for CME credit)
81. 260 - Long Term Neurologic Outcomes for Patients Receiving CAR-T Therapy for Non-Hodgkin’s Lymphoma Who Developed Severe Neurotoxicity
82. CAR T cell viability release testing and clinical outcomes: is there a lower limit?
83. CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before
84. Radiation-Based Approaches As an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis
85. Anti-CD19 CAR-T for Treatment of Double Expressor and Double Hit Large B-Cell Lymphomas: A Single Institution Real-World Analysis
86. Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study)
87. Impact of Radiotherapy on Hospitalization Burden Surrounding Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
88. Outcomes of COVID-19 in patients with CLL: a multicenter international experience
89. BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte)
90. Don't Get Stuck on the Shoulder: Radiation Oncologists Should Get Into the CAR With T-Cell Therapies
91. Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy.
92. 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma.
93. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support
94. Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement
95. Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization
96. A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
97. Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution
98. Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Multicenter Retrospective Analysis
99. Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
100. Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.